<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639716</url>
  </required_header>
  <id_info>
    <org_study_id>NG63900</org_study_id>
    <secondary_id>NG6420</secondary_id>
    <secondary_id>NG6420</secondary_id>
    <nct_id>NCT01639716</nct_id>
  </id_info>
  <brief_title>Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers</brief_title>
  <official_title>Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nil Guler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guler, Nil, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So&#xD;
      that the investigators decided to study of cytokines related to T helper 2 pathways. It is&#xD;
      well known that parasites and allergic situations also use T helper 2 pathways. Because that&#xD;
      the investigators excluded the patients have parasites and allergic situations. All the&#xD;
      patients were over 18. The investigators included the patients with non Hodgkin lymphoma&#xD;
      which new diagnosed. It is observational study. The investigators took blood before&#xD;
      chemotherapy and four months later. The investigators did not interfere with which&#xD;
      chemotherapy will be given to patients. This decision was belong to hematologist or&#xD;
      oncologist who will treat the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma</measure>
    <time_frame>This study ended within 13 months</time_frame>
    <description>We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survey as months</measure>
    <time_frame>During study which was 13 months</time_frame>
    <description>Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lymphoma group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-10 high</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-10 low</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-4 high</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-4 low</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphopenia</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      periperal blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        31 newly diagnosed non hodgkin lymphoma and 27 healthy controls. We studied IL-10 and IL-4&#xD;
        in lymphoma group and healthy group and observed patients till end of study. We analised&#xD;
        survival. We compared with IL-4 and IL-10 levels with prognostic factors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed non hodgkin lymphoma&#xD;
&#xD;
          -  Diffuse large B cell lymphoma and T cell lymphoma patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 18 age&#xD;
&#xD;
          -  parasitosis&#xD;
&#xD;
          -  allergic status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nil Guler, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Nil Guler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ONDOKUZ MAYİS UNİVERSİTY, SCHOOL OF MEDİCİNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ondokuz Mayis University Medical School</name>
      <address>
        <city>Samsun</city>
        <state>Atakum</state>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.omu.edu.tr</url>
    <description>OMU School of Medicine. Contact via e-mail.</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 4, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guler, Nil, M.D.</investigator_affiliation>
    <investigator_full_name>Nil Guler</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Survey, interleukin status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

